Kornimate/medical-research-clean huggingface dataset:
the effects of non-invasive brain stimulation on treatment adherence in schizophrenia

Conditions: Schizophrenia;Schizoaffective

Summary: this study seeks to explore the effects of transcranial direct current stimulation (tdcs), a non-invasive method of brain stimulation, as an adjunctive treatment to improve antipsychotic medication adherence in patients with schizophrenia (scz). the investigators hypothesize that 20 sessions of tdcs will improve medication nonadherence in patients with scz.

the proposed study will investigate the effects of adjunctive tdcs on antipsychotic medication adherence by targeting brain regions implicated in impaired insight, a primary contributor to medication nonadherence in patients with scz. participants will be randomized to receive either active or sham tdcs. tdcs will be administered twice-daily for 10 days (20 sessions) excluding weekends. brain scans will be performed before and after 10 days of tdcs. antipsychotic drug adherence will be assessed based primarily on pill-count, and secondarily, plasma level concentrations and clinician-judgement.

Eligibility criteria:
inclusion criteria: 1. male or female participants of any race or ethnicity 2. inpatients or outpatients ≥18 years of age 3. dsm-v diagnosis of scz or schizoaffective disorder 4. capable of consenting to participate in the research study 5. on a stable dose of antipsychotic drug and other concomitant medications for at least 2 months, and unlikely to undergo changes in dose during the study exclusion criteria: 1. unwilling or incapable to consent to the study based on the macarthur test of competence 2. unstable medical or any concomitant major medical or neurological illness, including a history of seizures 3. acute suicidal or homicidal ideation 4. formal thought disorder rating ≥3 on the positive and negative syndrome scale (panss) p2 conceptual disorganization item 5. dsm-v substance dependence (except caffeine and nicotine) within 1 month of entering the study\* 6. positive urine drug screen except for cannabis/marijuana at the screening visit 7. metal implants or pacemaker precluding an mri scan or other contraindications to mri (eg., claustrophobia) 8. pregnancy 9. score \< 32 on the wide range achievement test-iii * substance misuse: in addition to impaired insight, substance misuse is one of the principle contributors to medication nonadherence. to minimize the possibility of its influence, participants with a dsm-v diagnosis of substance dependence within 1 month of entering the study or a positive urine drug test (except for cannabis/marijuana) at the screening visit will be excluded. substance use and urine drug screens will be assessed at subsequent study visits.

Keywords: magnetic resonance imaging brain stimulation medication adherence
an ascending dose study of pit565 in participants with systemic lupus erythematosus (sle).

Conditions: Systemic Lupus Erythematosus, SLE

Summary: the purpose of the study is to determine the safety, tolerability, and pharmacokinetics of pit565 in participants with sle

this is an open-label, ascending dose, uncontrolled study in participants with sle systemic lupus erythematosus (sle). pit565 will be administered subcutaneously (s.c.) following premedication. up to 8 cohorts are planned. every cohort will have 3 sentinel participants and, depending on safety as well as observed biological activity, may have up to 3 additional optional participants (up to 6 participants per cohort). the decision to escalate the dose from one cohort to the next will be based both on safety and pd data. after the identification of a dose level that has been declared safe and has induced predefined b cell depletion in 100% of the participants (candidate dose level), the cohort from this candidate dose level can optionally be enriched with 6 additional participants (up to a total of 12 participants).

Eligibility criteria:
inclusion criteria: * diagnosis of sle according to the 2019 acr/eular criteria * documentation of sle autoantibodies * active sle disease, as demonstrated by a sledai-2k ≥ 4 at screening * failure to respond to standard-of-care medicines for the treatment of sle as detailed in the protocol * immunization against pneumococcus, influenza, and covid-19 exclusion criteria: * severe sle-related organ damage dysfunction or life-threatening disease at screening. * any acute, severe lupus-related flare during screening that needs immediate treatment such as acute cns lupus (e.g., psychosis, epilepsy) or catastrophic antiphospholipid syndrome. * presence of severe lupus kidney disease as defined by worsening proteinuria or estimated glomerular filtration rate (egfr) which in the opinion of the investigator requires immune-suppressive induction or maintenance treatment at screening. * history or current diagnosis of ecg or cardiac abnormalities indicating a significant risk of safety for participants. * use of prohibited medication defined in the protocol. * clinically significant active, opportunistic, chronic or recurrent infection (including, hiv, hbv, hcv) confirmed one month prior to or during screening. * serious medical illness likely to interfere with participation in this clinical study. * women of child-bearing potential, defined as all women physiologically capable of becoming pregnant from menarche until becoming post-menopausal, unless they are using highly effective methods of contraception other protocol defined inclusion/exclusion criteria may apply.

Keywords: systemic lupus erythematosus, sle, ascending dose, b cells
utilizing smart devices to identify new phenotypical characteristics in movement disorders

Conditions: Parkinson Disease; Essential Tremor; Movement Disorders; Parkinson's Syndrome; Atypical Parkinsonism

Summary: this observational and experimental study seeks to establish a smart device system (sds) to monitor high-resolution handtremor-based data using smartphones, smartwatches and tablets. by doing this, movement data will be analyzed in depth with advanced statistical and deep-learning algorithms to identify new clinical phenotypical characteristics parkinson's disease and essential tremor.

current smart devices as smartphones and smartwatches have reached a level of technical sophistication that enables high-resolution monitoring of movements not only for everyday sports activities but also for movement disorders. tremor-related diseases as parkinson's disease (pd) and essential tremor (et) are two of the most common movement disorders. disease classification is primarily based on clinical criteria and remains challenging. the primary goal of this study is to identify new phenotypical characteristics based on the captured movement data by the tremor-capturing smartwatches and tablets and smartphone-based questionnaires. the system will be applied and analyzed within an experimental and observational setting and only captures from patients, which have received informed consent. within the study period, the sds is not intended as clinical diagnostic support for physicians and will be not be used as medical device.

Eligibility criteria:
inclusion criteria: * diagnosed with parkinson's disease (icd-10-gm g20.-) or essential tremor (g25.0) * comparison group: other movement disorders including atypical parkinsonian disorders and healthy participants exclusion criteria: * unable to obtain informed consent * skin-related conditions at one of the wrists or any other medical conditions that could harm the participant's health by wearing the smartwatch at both wrists.
nice - nutritional impact on immunological maturation during childhood in relation to the environment

Conditions: Chronic Diseases in Children

Summary: role of the exposome on allergy, caries, and neurophysiological development in childhood.

role of the exposome and epigenetics on allergy, caries, and neurophysiological development in childhood as studied in a birth cohort of 650 trioses. the exposome includes repeated measures of nutrition, micronutritients, microbiota, toxic agents and the clinical outcomes, diagnoses of allergy, caries and neurophysiological functions/dysfunctions.

Eligibility criteria:
inclusion criteria: * born at sunderby hospital, region norrbotten, during time period 2015-2018 exclusion criteria: * parents not able to speak or write swedish
transdiagnostic treatment personalization

Conditions: Anxiety Disorders; Depressive Disorder; Post Traumatic Stress Disorder; Obsessive-Compulsive Disorder

Summary: the primary purpose of this study is to explore whether the efficiency of treatment for anxiety and depressive disorders can be increased using two discrete strategies: personalized skill ordering and 2) treatment discontinuation based on proximal indicators of improvements. the present study will specifically use treatment components drawn from an evidence-based psychological intervention, the unified protocol for the transdiagnostic treatment of emotional disorders (up). this intervention has strong empirical support for patients presenting with anxiety, depressive, and related disorders and contains therapeutic skills that are common in psychological interventions (e.g., psychoeducation, mindfulness training, cognitive restructuring, countering emotional avoidance, increasing interoceptive tolerance). this study will determine if prioritizing the order of treatment modules to capitalize on patient strengths or compensate for weakensses increases treatmen efficacy. additionally, it will also identify under what conditions briefer treatment modules may be appropriate.


Eligibility criteria:
inclusion criteria: * diagnosis of at least one emotional disorder * fluent in english * medication stability exclusion criteria: * concurrent therapy * psychological condition that would be better addressed by alternative treatments * have received more than 5 sessions of cognitive behavioral therapy in the past 5 years

Keywords: unified protocol cognitive behavioral therapy personalization
kinesiotape for edema after bilateral total knee arthroplasty

Conditions: Arthroplasty Complications; Arthroplasty, Replacement, Knee

Summary: the purpose of this study is to determine if kinesiotaping for edema management will decrease post-operative edema in patients with bilateral total knee arthroplasty. the leg receiving kinesiotaping during inpatient rehabilitation may have decreased edema and pain and improved movement and function when compared to the leg not receiving kinesiotape.

after being informed about the study and potential risk, all patients undergoing inpatient rehabilitation after bilateral total knee arthroplasty will have kinesio(r)tape applied to one randomly selected leg while the other leg serves as a control. measurement of bilateral leg circumference, knee range of motion, numerical rating scale for pain, and selected questions from the knee injury and osteoarthritis outcome score will occur at regular intervals throughout the rehabilitation stay. patients will receive standard rehabilitation.

Eligibility criteria:
inclusion criteria: * admitted to burke rehabilitation hospital for inpatient rehabilitation within 5 days after same-day or staged bilateral total knee arthroplasty; * 50-85 years of age; * able to read and understand english or a hospital-provided translator when consenting for the study; * free from contraindications for kinesiotaping (see below); and, * able to tolerate an active rehabilitation program. exclusion criteria: * stage iii or iv heart failure, stage iii or iv renal failure; * fragile, very hairy or sensitive skin; * anesthesia or paraesthesia of any area of the lower extremity, except the surgical sites * active skin rashes or infections or skin lesions in the lower extremity; * prior history of allergic reactions to skin taping, bandaids, surgical tape; athletic tape or other skin-adhering electrode adhesives; * prior history of lower extremity lymphedema;3 * prior history of lower extremity venous or arterial disease; * post-operative complications in the surgical sites;4 * partial joint arthroplasty or revision arthroplasty of one or both knees;1,5 * inability to give informed consent offered in english or through a hospital-provided translator * age less than 50 years or over 85 years; * inability to tolerate an active rehabilitation program.

Keywords: edema arthroplasty, knee, bilateral kinesiotaping
effect of vardenafil on blood pressure in patients with erectile dysfunction who received concomitant doxazosin gits

Conditions: Prostatic Hyperplasia; Impotence

Summary: the purpose of this study is to investigate the interaction between doxazosin gits and vardenafil on blood pressure (both systolic and diastolic blood pressure) in patients with both ed and bph.


Eligibility criteria:
inclusion criteria: * age between 50 to 80 years old * clinically diagnosed to have lower urinary tract symptoms secondary to bph: 1. suffered from lower urinary tract symptoms with international prostate symptom score (ipss) \>=8 2. detectable prostatic enlargement determined by digital rectum examination (dre) 3. urinary flow between 5 to 15ml/second in a total void volume \>=150ml * currently on regular doxazosin gits once-daily for at least 4 weeks without clinically significant side effects * complaints of erectile dysfunction with erectile function domain (ef) of the international index of erectile function (iief) score \<= 21 exclusion criteria: * congestive heart failure, unstable angina, arrhythmia, myocardial infraction * hypertension or on any antihypertensive agents * take nitrate and medication contradicted to vardenafil * uncontrolled or poorly controlled diabetes mellitus * intolerance or contra-indicated for the use of vardenafil * hepatic disorder

Keywords: benign prostatic hyperplasia (bph) erectile dysfunction (ed)
an open-labeled trial of ramipril in patients with migraine

Conditions: Migraine With Hypertension

Summary: physiology of migraine involving renin-angiotensin systems (ras) has been implicated. ramipril is a broadly-used angiotensin-converting enzyme inhibitor. the investigators attempt to test the efficacy of ramipril on the prophylaxis of migraine attacks.


Eligibility criteria:
inclusion criteria: * patients with chronic migraine are included in this study. migraineurs should be aged 20 to 70 years old with the ability to read and understand the self-report scales, including the headache diary, used in this study. exclusion criteria: 1. medication overuse headache are excluded in this study. 2. treatment with other acei or medication that may affect ars 3. treatment with migraine prophylactic medications or anti-hypertensive agents including β adrenergic receptor or calcium channel blockers 4. past history of hepatic or renal dysfunction; an abnormal electrocardiography; a psychiatric disorder; a history of substance abuse; pregnancy or lactation; use of anti-psychotics, antidepressants, or anti-anxiety drugs.

Keywords: migraine, ramipril, hypertension
octa in epivascular glia after dex implant

Conditions: Diabetic Retinopathy

Summary: the aim of this prospective study was for the first time, to analyze specific morphologic features in diabetic eyes with macular oedema, such as changes of the foveal avascular zone and the presence of epivascular glia, and see how they would change after dexamethasone intravitreal implant


Eligibility criteria:
inclusion criteria: * diabetic retinopathy complicated by macular edema exclusion criteria: * congenital eye disorders, * previous diagnosis of other ocular diseases * history of vitreous hemorrhage
estradiol pretreatment with misoprostol in second trimester miscarriage

Conditions: Miscarriage

Summary: to compare the effectiveness of estradiol pretreatment with misoprostol and vaginal misoprostol alone in induction of second trimestr miscarriage.


Eligibility criteria:
inclusion criteria: * maternal age more than 18 years old (age of legal consent). * gestational age between 12-26 weeks. * hb level \> 10 g/dl. * bmi between 25 kg/m2 and 35 kg/m2. * missed abortion. * living fetus with multiple congenital malformations incompatible with life. * pproms with drained liquor and parents are consenting for termination of pregnancy. exclusion criteria: * maternal age less than 18 years old. * gestational age less than 12 weeks or more than 26 weeks. * hb level \< 10 g/dl. * scared uterus (previous myomectomy - cesarean section - hysterectomy and ruptured uterus). * polyhydramnios. * anencephaly. * fibroid uterus. * bmi less than 25 kg/m2 and more than 35 kg/m2. * coagulopathy. * previous attempts for induction of abortion in the current pregnancy. * allergy to misoprostol or estradiol. * placenta previa. * medical disorder that contraindicate induction of abortion (e.g. heart failure).
a study to compare the safety and imaging pattern of cyclotron-produced technetium (ctc) vs. generator-produced technetium (g-pert) in people with thyroid disorders who need surgery

Conditions: Thyroid Gland Diseases

Summary: a 99mtc pertechnetate (g-pert) scan is a nuclear medicine test that can create an image of the thyroid gland and other organs. g-pert is approved by health canada for the direct imaging and measurement of thyroid uptake. doctors and researchers at the university of alberta have developed a new method of producing 99mtc pertechnetate (called ctc). it is made in a cyclotron at the medical isotope and cyclotron facility (micf) at the university of alberta, edmonton, alberta. this new production method will provide another source of 99mtc pertechnetate. the aim of this study is to confirm that ctc is safe and can be used interchangeably with g-pert.

the clinical trial will be a phase iii, prospective, crossover, image interpretation blinded, single site study. all subjects will receive tc-99m pertechnetate (one ctc and one g-pert administration separated by at least 48 hours) and subsequently be imaged for thyroid uptake and whole body biodistribution. the order of the scans will be randomized. the thyroid image will be interpreted for uptake / no uptake in the thyroid, and the whole body biodistribution image will be interpreted for uptake / no uptake in selected anatomical sites. interpretation of thyroid imaging results will be compared with other clinical findings (such as pre-surgical ultrasound, fine needle aspirate, and post-surgical pathology results, when available). all imaging assessments will be conducted by 1 blinded nuclear medicine physician. a safety evaluation will be conducted on all subjects receiving ctc, consisting of vital signs, haematology and sma-12 serum biochemistry profile (pre-injection and post-imaging), and, for both ctc and g-pert, an adverse event assessment (until the subject leaves the nuclear medicine department) after each administration.

Eligibility criteria:
inclusion criteria: 1. male or female ≥ 18 years of age and \< 80 years of age. 2. have a proven or suspected thyroid pathology that requires surgery by standard clinical criteria. 3. able and willing to follow instructions and comply with the protocol. 4. provide written informed consent prior to participation in the study. exclusion criteria: 1. nursing or pregnant females.
molecular characterization of induced neuronal cells in parkinson's disease

Conditions: Parkinson Disease

Summary: to describe the molecular, electrophysiological and morphological expression profile of dopaminergic neurons derived from fibroblasts of patients with parkinson's disease.


Eligibility criteria:
inclusion criteria: 1. subjects aged 18 years or older 2. patients with parkinson's disease, according to the most recent diagnostic criteria 3. evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study exclusion criteria: 1. patients affected by drug-induced parkinsonism or atypical parkinsonian disorders 2. patients with neurological diseases other than parkinson's disease 3. inability to sign an informed consent 4. severe psychiatric diseases
safety study of sgx523, a small molecule met inhibitor, to treat solid tumors

Conditions: Advanced Cancer

Summary: sgx523 is a drug which acts by blocking the function of an enzyme called met. met activity may be important in growth and survival of some types of cancer. this phase i trial is studying the safety, side effects, and best dose of sgx523 when given to patients with advanced cancer, and how well it inhibits met activity in tumors.


Eligibility criteria:
inclusion criteria: * subject has the ability to understand, able, willing to comply with study procedures and follow up visits, and has provided written consent * pathologic evidence of solid tumor * failed standard therapy and deemed by the investigator to be suitable for participation into the trial * laboratory values (obtained within 10 days prior to enrollment): anc: \>= 1.5 × 109/l; platelets: \>= 100 × 109/l; hemoglobin: \>= 10.0 g/dl (without transfusions); bilirubin: within normal range; ast, alt, and alkaline phosphatase: \ = 60 ml/min/1.73 m2 for patients with creatinine \> institutional normal values; pt/ptt/inr: within normal limits.. * have ihc evidence of phospho-met expression on tumor material no more than 12 months old. this is a requirement only for entry into the mtd dose expansion phase. * have no residual toxic effects of previous therapy, and undergo a washout period of at least 5 half-lives from the time of administration of the previous therapy. exclusion criteria: * pregnant, lactating, or may become pregnant * cardiac disease requiring medical therapy * have had a major surgery within 4 weeks prior to day 1 of the study * have an active, uncontrolled bacterial, viral, or fungal infection that requires ongoing systemic therapy * have a known active infection with hiv, hepatitis b or c * have psychiatric or seizure disorders that would require therapy or interfere with study participation * have other severe concurrent nonmalignant disease that could compromise protocol objectives, including malabsorptive conditions * patients receiving prohibited medications as listed in appendix e, including drugs categorized as strong inhibitors of cyp3a4 and a5 and drugs known to have a high potential risk of liver toxicity * have known allergy to sgx523 formulation or its excipients (croscarmellose sodium, lactose monohydrate and magnesium steareate) * patients receiving anti-coagulant therapy

Keywords: solid tumor advanced cancer met inhibitor receptor tyrosine kinase inhibitor (rtki)